


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31198406</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1475-2867</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer cell international</Title>
                <ISOAbbreviation>Cancer Cell Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>157</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12935-019-0870-6</ELocationID>
            <Abstract>
                <AbstractText>Fibromodulin (FMOD) is known as one of very important extracellular matrix small leucine-rich proteoglycans. This small leucine-rich proteoglycan has critical roles in the extracellular matrix organization and necessary for repairing of tissue in many organs. Given that the major task of FMOD is the modulation of collagen fibrillogenesis. However, recently observed that FMOD plays very important roles in the modulation of a variety of pivotal biological processes including angiogenesis, regulation of TGF-Î² activity, and differentiation of human fibroblasts into pluripotent cells, inflammatory mechanisms, apoptosis and metastatic related phenotypes. Besides these roles, FMOD has been considered as a new tumor-related antigen in some malignancies such as lymphoma, leukemia, and leiomyoma. Taken together, these findings proposed that FMOD could be introduced as diagnostic and therapeutic biomarkers in treatment of various cancers. Herein, for first time, we highlighted the various roles of FMOD in the cancerous conditions. Moreover, we summarized the diagnostic and therapeutic applications of FMOD in cancer therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Pourhanifeh</LastName>
                    <ForeName>Mohammad Hossein</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0612 1049</Identifier>
                        <Identifier Source="GRID">grid.444768.d</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Mohammadi</LastName>
                    <ForeName>Rezvan</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Department of Medical Biotechnology and Molecular Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0459 3173</Identifier>
                        <Identifier Source="GRID">grid.464653.6</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Noruzi</LastName>
                    <ForeName>Somaye</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Department of Medical Biotechnology and Molecular Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0459 3173</Identifier>
                        <Identifier Source="GRID">grid.464653.6</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Hosseini</LastName>
                    <ForeName>Seyede Atefe</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Department of Medical Biotechnology and Molecular Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0459 3173</Identifier>
                        <Identifier Source="GRID">grid.464653.6</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fanoudi</LastName>
                    <ForeName>Sahar</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>3Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0001 2198 6209</Identifier>
                        <Identifier Source="GRID">grid.411583.a</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohamadi</LastName>
                    <ForeName>Yousef</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>4Department of Anatomy, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0384 871X</Identifier>
                        <Identifier Source="GRID">grid.444830.f</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hashemzehi</LastName>
                    <ForeName>Milad</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Iranshahr University of Medical Sciences, Iranshahr, Iran.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>6Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0001 2198 6209</Identifier>
                        <Identifier Source="GRID">grid.411583.a</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asemi</LastName>
                    <ForeName>Zatollah</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0612 1049</Identifier>
                        <Identifier Source="GRID">grid.444768.d</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mirzaei</LastName>
                    <ForeName>Hamid Reza</ForeName>
                    <Initials>HR</Initials>
                    <AffiliationInfo>
                        <Affiliation>7Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0001 0166 0922</Identifier>
                        <Identifier Source="GRID">grid.411705.6</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salarinia</LastName>
                    <ForeName>Reza</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Department of Medical Biotechnology and Molecular Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0459 3173</Identifier>
                        <Identifier Source="GRID">grid.464653.6</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mirzaei</LastName>
                    <ForeName>Hamed</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0612 1049</Identifier>
                        <Identifier Source="GRID">grid.444768.d</Identifier>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Cancer Cell Int</MedlineTA>
            <NlmUniqueID>101139795</NlmUniqueID>
            <ISSNLinking>1475-2867</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer</Keyword>
            <Keyword MajorTopicYN="N">Diagnosis</Keyword>
            <Keyword MajorTopicYN="N">Fibromodulin</Keyword>
            <Keyword MajorTopicYN="N">Therapy</Keyword>
        </KeywordList>
        <CoiStatement>Competing interestsThe authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31198406</ArticleId>
            <ArticleId IdType="doi">10.1186/s12935-019-0870-6</ArticleId>
            <ArticleId IdType="pii">870</ArticleId>
            <ArticleId IdType="pmc">PMC6558739</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

